StreetInsider.com News Articles

Form 8-K KIORA PHARMACEUTICALS For: Oct 23

Thu, 29 Oct 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20261029/27252514.html

Kiora licenses oral eye drug from Senju for rare retinal condition

Thu, 29 Oct 2026 07:03:35 -0400

Kiora Pharmaceuticals (NASDAQ: KPRX) has obtained exclusive rights to develop and commercialize KIO-401 (mitucapistat), an oral calpain inhibitor, outside Asia from Senju Pharmaceutical Co., Ltd. The drug is being developed as a potential treatment for central retinal artery occlusion (CRAO), a rare condition that can cause severe, permanent vision loss and currently has no approved therapies.

Under the license agreement, Kiora will pay Senju an upfront fee of $3.5 million, followed by a one-time milestone payment in the low teen millions upon technology transfer expected in 2027. Senju is also eligible for additional regulatory and commercial milestone payments, plus single-digit royalties

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri

Thu, 29 Oct 2026 07:00:00 -0400

The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.
No therapeutics exist today to treat patients that experience CRAO vision loss.
Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.
Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic neuropathy ("NAION").

San Diego, California--(Newsfile Corp. - October 29, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has obtained exclusive development

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri

Thu, 29 Oct 2026 07:00:00 -0400

The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.
No therapeutics exist today to treat patients that experience CRAO vision loss.
Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.
Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic neuropathy ("NAION").

San Diego, California--(Newsfile Corp. - October 29, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has obtained exclusive development

Form 4 KIORA PHARMACEUTICALS For: Sep 17 Filed by: Lane Keith J.

Thu, 17 Sep 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260917/27077273.html

Form 3 KIORA PHARMACEUTICALS For: Sep 08 Filed by: Lane Keith J.

Thu, 17 Sep 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260917/27077255.html

Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: Baselake Partners, LP

Thu, 17 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260917/27075895.html

Kiora Pharmaceuticals names new clinical development chief

Tue, 08 Sep 2026 07:02:20 -0400

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced the appointment of Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs, according to a company statement.

Lane joins Kiora from Ora, Inc., an ophthalmology-focused clinical research organization, where he served as Chief Scientific Officer. During his tenure at Ora, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission.

Lane holds an MBA in health sector management from Boston University's Questrom School of Business and a Bachelor of

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Tue, 08 Sep 2026 07:00:00 -0400

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities

Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials.

"Keith has substantial experience supporting U.S. and global clinical programs across retinal

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Tue, 08 Sep 2026 07:00:00 -0400

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities

"Keith has substantial experience supporting U.S. and global clinical programs across retinal

Form 8-K KIORA PHARMACEUTICALS For: Aug 19

Wed, 19 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26947090.html

Form 8-K KIORA PHARMACEUTICALS For: Aug 19

Wed, 19 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26947090.html

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Wed, 19 Aug 2026 07:00:00 -0400

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regulatory milestone payments, as well as royalties on future sales of KIO-301 in South Korea.

"KIO-301 is a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells through a

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Wed, 19 Aug 2026 07:00:00 -0400

"KIO-301 is a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells through a

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26932513.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26932513.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932142.html

Form SCHEDULE 13G/A KIORA PHARMACEUTICALS Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932142.html

Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20260810/26896335.html

Form SCHEDULE 13G KIORA PHARMACEUTICALS Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20260810/26896335.html

Kiora Pharmaceuticals (KPRX) Tops Q2 EPS by 17c

Fri, 07 Aug 2026 07:34:27 -0400

Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 EPS of ($0.34), $0.17 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Kiora Pharmaceuticals (KPRX) click here.

Form 8-K KIORA PHARMACEUTICALS For: Aug 07

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887375.html

Form 8-K KIORA PHARMACEUTICALS For: Aug 07

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887375.html

Form 10-Q KIORA PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887370.html

Form 10-Q KIORA PHARMACEUTICALS For: Jun 30

Fri, 07 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26887370.html